IBUPROFEN AND PSEUDOEPHEDRINE TABLET

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

Доступно од:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

АТЦ код:

M01AE51

INN (Међународно име):

IBUPROFEN, COMBINATIONS

Дозирање:

200MG; 30MG

Фармацеутски облик:

TABLET

Састав:

IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG

Пут администрације:

ORAL

Јединице у пакету:

20/40

Тип рецептора:

OTC

Терапеутска област:

ALPHA-AND BETA-ADRENERGIC AGONISTS

Резиме производа:

Active ingredient group (AIG) number: 0222394001; AHFS:

Статус ауторизације:

CANCELLED POST MARKET

Датум одобрења:

2016-01-22

Карактеристике производа

_ _
_ Page 1 _
PRODUCT MONOGRAPH
IBUPROFEN AND PSEUDOEPHEDRINE
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
TABLETS
USP
200MG & 30 MG
Therapeutic Classification
ANALGESIC/ANTIPYRETIC/NASAL DECONGESTANT
McNeil Consumer Healthcare
88 McNabb Street
Markham, Ontario L3R 5L2
Date of Preparation:
January 18, 2007
Control # 111161
© McNeil Consumer Healthcare 2006
_ _
_ _
_Page 2 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................7
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND
ADMINISTRATION..............................................................................12
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND
STABILITY..........................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
PART II: SCIENTIFIC INFORMATION
...............................................................................17
PHARMACEUTICAL
INFORMATION..........................................................................17
CLINICAL
TRIALS..........................................................................................................18
DETAILED